Endocrine therapy drugs are used to treat hormone-sensitive cancers such as breast cancer, prostate cancer and ovarian cancer by blocking the body's natural hormones or by lowering hormone levels. These drugs play an important role in the long-term treatment and management of various cancers. With rising cancer cases worldwide, the need for effective endocrine therapy drugs has increased significantly.
The global Endocrine Therapy Drugs (ETDS) Market is estimated to be valued at US$ 35060.96 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends driving the growth of the Endocrine Therapy Drugs (ETDS) Market is the increasing prevalence of cancer globally. According to WHO, cancer is the second leading cause of death worldwide and the number of new cancer cases is expected to rise by over 70% in the next two decades. Breast cancer is the most common cancer in women with over 2 million new cases diagnosed in 2018 alone according to global cancer statistics. Rising pollution levels, changing lifestyle habits and growing geriatric population are major factors contributing to the increasing burden of cancer worldwide which in turn is fueling the demand for effective drugs like endocrine therapy drugs for long term treatment of cancer patients. This growing prevalence of cancer is expected to accelerate the growth of the Endocrine Therapy Drugs (ETDS) Market over the forecast period.
Segment Analysis
The global Endocrine Therapy Drugs (ETDS) Market is dominated by hormone therapy sub-segment. Hormone therapy is the most common type of endocrine therapy used to treat hormone receptive breast cancer. It involves using drugs to block the effects of estrogen or progesterone on breast cancer cell growth. Hormone therapy is very effective in treating hormone-receptive breast cancers as it targets the specific hormones that help cancer cells grow.
Key Takeaways
Global Endocrine Therapy Drugs (ETDS) Market Size is expected to witness high growth over the forecast period of 2024 to 2031. The global Endocrine Therapy Drugs (ETDS) Market is estimated to be valued at US$ 35060.96 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.
Regional Analysis
North America currently dominates the global Endocrine Therapy Drugs (ETDS) Market due to rising prevalence of breast cancer and presence of major market players. According to American Cancer Society, over 276,480 new cases of breast cancer were diagnosed in the US in 2022. The region is expected to continue its dominance over the forecast period owing to growing adoption of advanced hormone therapies and increasing research investments for new drug development.
Key Players Analysis
Key players operating in the Endocrine Therapy Drugs (ETDS) Market are Johnson & Johnson (US), Procter & Gamble (US), Kimberly-Clark (US), Essity Aktiebolag (publ) (Sweden), Kao Corporation (Japan), Daio Paper Corporation (Japan), Unicharm Corporation (Japan), Premier FMCG (South Africa), Ontex (Belgium), Hengan International Group Company Ltd. (China), Drylock Technologies (Belgium), Natracare LLC (US), First Quality Enterprises, Inc. (US), Bingbing Paper Co., Ltd. (China). Johnson & Johnson and Procter & Gamble currently hold majority market share due to their diverse hormone therapy drug portfolio and strong global presence.
Explore More Related Article On This Topic: https://www.pressreleasebulletin.com/endocrine-therapy-drugs-market-size/
Explore More Related Article: https://medium.com/@gauri.cmi01/the-global-training-market-growth-accelerated-by-leveraging-ai-and-analytics-technologies-6028c29126b3
Comments
0 comment